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ABSTRACT
Human epidermal growth factor receptor 2 (HER2)
overexpression is present in approximately 15% of early
invasive breast cancers, and is an important predictive
and prognostic marker. The substantial beneﬁts achieved
with anti-HER2 targeted therapies in patients with
HER2-positive breast cancer have emphasised the need
for accurate assessment of HER2 status. Current data
indicate that HER2 test accuracy improved following
previous publication of guidelines and the
implementation of an external quality assessment
scheme with a decline in false-positive and false-
negative rates. This paper provides an update of the
guidelines for HER2 testing in the UK. The aim is to
further improve the analytical validity and clinical utility
of HER2 testing by providing guidelines of test
performance parameters, and recommendations on the
postanalytical interpretation of test results. HER2 status
should be determined in all newly diagnosed and
recurrent breast cancers. Testing involves
immunohistochemistry with >10% complete strong
membrane staining deﬁning a positive status. In situ
hybridisation, either ﬂuorescent or bright ﬁeld
chromogenic, is used either upfront or in
immunohistochemistry borderline cases to detect the
presence of HER2 gene ampliﬁcation. Situations where
repeat HER2 testing is advised are outlined and the
impact of genetic heterogeneity is discussed. Strict
quality control and external quality assurance of
validated assays are essential. Testing laboratories should
perform ongoing competency assessment and proﬁciency
tests and ensure the reliability and accuracy of the assay.
Pathologists, oncologists and surgeons involved in test
interpretation and clinical use should adhere to
published guidelines and maintain accurate performance
and consistent interpretation of test results.
INTRODUCTION
Overexpression of the human epidermal growth
factor receptor 2 (HER2) protein, mainly due to
HER2 gene ampliﬁcation, in breast cancer is asso-
ciated with aggressive histological features and
poor prognosis.1 2 Several randomised clinical trials
have demonstrated substantial survival beneﬁts in
patients with HER2-positive breast cancer treated
with anti-HER2 targeted therapy, such as trastuzu-
mab3–5 and the tyrosine kinase inhibitor
lapatinib6–8 but not in HER2-negative patients.9
This, in addition to potential side effects of these
costly drugs and evidence of higher response rates
to neoadjuvant chemotherapy in HER2-positive
tumours,10 has emphasised the need for accurate
assessment of HER2 status in patients with all-inva-
sive breast cancer. Early studies, with relatively
small numbers of cases, suggested that as many as
30% of breast cancers had HER2 overexpression,
with a false positive rate up to 19% and a false
negative rate of 5–10%.11–13 However, following
publication of guideline recommendations11 14–18
and reﬁnement of test performance parameters
including the standardisation of tissue handling,
assay methodology and adopting quality assurance
measures, recent data indicate that the frequency of
HER2 positivity is between 13% and 20%.11 12 19–21
The false positive rate is reduced to less than 6%,
the false negative rate is much lower (<2%) and,
importantly, the proportion of inconclusive cases is
signiﬁcantly reduced.11 12 19 20 To ensure the
highest degree of test accuracy, reproducibility and
precision, there is a need to further standardise and
improve the quality of technical aspects such as
assay performance, validation, proﬁciency testing
and accreditation. These guidelines, which are pre-
sented on behalf of the UK National Coordinating
Committee for Breast Pathology, aim to update the
previous UK guidelines14–16 and provide recom-
mendations on the preanalytical and postanalytical
assay performance parameters and give advice on
methodology and quality assurance measures for
HER2 testing.
PREANALYTICAL MEASURES
Specimens
HER2 status should be assessed in all invasive
primary breast carcinomas and in recurrent and
metastatic tumours whenever biopsy tissue is avail-
able. Bilateral carcinomas, histologically distinct
ipsilateral carcinomas or widely separated carcin-
omas considered to be separate synchronous
primary tumours should each be assessed. It is
deemed reasonable not to assess multiple ipsilateral
tumours if they are histologically similar and colo-
cated in the same quadrant/region of the breast.
There is no consensus on testing residual invasive
tumour following neoadjuvant therapy, although
some recommend this approach. Retesting non-
responding stable or progressive HER2-negative
tumours particularly high-grade tumours or those
with a long time period between preoperative
biopsy and excision may be considered but cannot
be recommended routinely in view of the lack of
evidence.
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Excellent concordance between core biopsy and surgical spe-
cimens has been shown using immunohistochemistry (IHC) and
in situ hybridisation (ISH).20 22 23 In the majority of UK
centres, HER2 testing is performed on the diagnostic needle
core biopsy specimens, mainly to ensure timely availability of
results at the time of postoperative multidisciplinary team
(MDT) treatment planning discussion and also to enable consid-
eration for neoadjuvant treatment use which is increasingly used
for operable cases. Although assessment of HER2 status on
needle core biopsy is recommended and no repeat on excision
specimens is needed if the test is clearly positive or negative,
performing/repeating the assay on incisional or excisional surgi-
cal specimens should be considered if:
(1) the core biopsy is not available (ie, there is only a cytology
sample); or (2) there is a possibility that the HER2 test on the
core biopsy is unreliable or unrepresentative of the tumour iden-
tiﬁed in the resection specimen as follows:
1. HER2 assessment is uninterpretable on the core due to tech-
nical artefacts (ie, suboptimal processing or staining) or there
is doubt about the core biopsy handling.
2. The core biopsy HER2 status remains in the equivocal cat-
egory after IHC and ISH; for example, repeat assessment is
advised if the core biopsy was scored as 2+ on HER2 IHC
with borderline negative ISH (ratio of number of HER2 to
chromosome 17 centromere copies of 1.8–1.99 or HER2
gene copy number is 4–6).
3. Invasive tumour on the core is too small for reliable assess-
ment, or if invasive disease is intimately admixed with in
situ carcinoma, or only identiﬁed in the excision specimen.
There is insufﬁcient data to deﬁne the amount of invasive
tumour tissue in core biopsy sufﬁcient for analysis; however
this can be left to the reporting pathologist’s discretion.
4. If the tumour in the resection specimens is morphologically
distinct from that in the core biopsy, for example of a clearly
different histological type or histological grade (eg, low
grade on the core and high grade on the excision, but not
just reﬂecting minor difference in the mitotic count or pro-
portion of solid areas).24 A repeat may also be undertaken
on concurrent metastatic nodal disease if it is morphologic-
ally distinct from the primary breast tumour.
5. If the core biopsy staining is heterogeneous and shows a
focus of strong HER2 positivity in <10% of the area of the
invasive carcinoma in the core biopsy, HER2 testing should
be repeated on the excision specimen. If this pattern is
detected on the excision specimen, a different tumour block
or a nodal metastasis can be tested, to determine the per-
centage of positive/ampliﬁed tumour present in a larger
tumour sample.
Fine needle aspirates from primary breast carcinoma are not
suitable for assessment of HER2 status as the distinction
between invasive and in situ disease cannot be made on such
samples. However, if ﬁne needle aspiration (FNA) is the only
material available, or in metastatic disease, some evidence indi-
cates that ISH is reliable for assessing HER2 status in liquid-
based and cell block preparations.25 In the case of metastatic
bone lesions that require HER2 assessment, it should be noted
that decalciﬁcation techniques have the potential to inﬂuence
immunohistochemical assessment in a detrimental manner and
such decalciﬁed samples should be tested with ISH
methods.26 27
Fixation and processing
Good ﬁxation of specimens used for HER2 testing should be
ensured and the cold ischaemic time (time from removal from
the patient to placing in ﬁxative (cold ischaemic time)) should
be as short as possible, certainly less than 1 h.28 Formalin ﬁxed,
parafﬁn embedded tumour tissue samples are appropriate for
assay. Tumours samples should be ﬁxed in buffered formalin
and embedded in parafﬁn wax; ﬁxatives containing alcohol can
result in staining of normal tissue and use of Bouin’s ﬁxative
will preclude testing by ﬂuorescence in situ based methods.
Other methods of tissue ﬁxation can also adversely affect
antigen reactivity. At least 6 h ﬁxation is recommended for core
biopsies. Surgical specimens should be incised as soon as pos-
sible through the carcinoma to allow initial penetration of ﬁxa-
tive and then sliced into 5–10 mm slices to ensure rapid
penetration and even ﬁxation. Tissue should be placed in an
adequate volume (ideally 10:1; ﬁxative:tissue) of ﬁxative for at
least 24 h and not more than 72 h Centres using rapid ﬁxation
and processing must validate their methodology for HER2
assessment.
Sections should be stained within 1–2 days of cutting and
drying. Excessive section drying time has also been shown to
cause a loss of HER2 expression and it is therefore recom-
mended that freshly cut sections are either dried at 60°C for 1 h
or 37°C overnight29 (http://www.ukneqasicc.ucl.ac.uk/neqasicc.
shtml).
ALGORITHMS FOR HER2 TESTING
IHC for detection of protein overexpression and ISH for detec-
tion of gene ampliﬁcation status are the techniques recom-
mended for determining HER2 status. High concordance
between IHC and gene ampliﬁcation status is reported.16 30 31
The current UK recommendations for HER2 testing are for a
two-tier system using IHC with reﬂex ISH testing if required,
using the model shown in ﬁgure 1, or a one-tier ISH strategy. In
general testing is performed using IHC with analysis of equivo-
cal cases by ISH, but this does not preclude laboratories from
using primary HER2 ISH testing, particularly if the quality of
tissue ﬁxation is questionable.32 ISH has usually been conducted
using a ﬂuorescence ISH (FISH) technique. Bright-ﬁeld ISH,
which can be used to assess HER2 status with a regular light
microscope, is now accepted as an alternative to FISH.33 The
most common bright ﬁeld ISH uses a DNA probe coupled to a
chromogenic ISH or silver ISH detection system, or a combin-
ation of both.33 ISH can be conducted using a single probe to
enumerate HER2 copies per nucleus or as a dual-probe tech-
nique which allows determination of the HER2:CEP17 ratio
and HER2 gene copy number. For this reason the inclusion of a
chromosome 17 probe is strongly advocated. Currently, other
available HER2 testing techniques (PCR, ELISA, Southern blot-
ting, mRNA assays and DNA microarray) should be used for
research only. Similarly, HER2 results obtained from a non-ISH
technique as part of a prognostic panel cannot be regarded as
diagnostic and should not replace standard assay methods
detailed above.
Scoring immunohistochemistry
Only membrane staining of the invasive tumour should be con-
sidered when scoring HER2. Cytoplasmic staining and staining
of in situ disease should not be scored, and normal epithelium
should be negative. The HER2 IHC scoring method is a semi-
quantitative system based on the intensity of reaction product
and percentage of membrane positive cells, giving a score range
of 0–3+ (ﬁgure 1). Samples scoring 3+ are regarded as
unequivocally positive, and those scoring 0/1+ as negative.
Borderline scores (2+) are regarded as equivocal and mandate
further assessment using ISH (ﬁgure 1). Appropriate controls
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featuring different scores (3+, 2+ and 1+/0) should be
included in every test run. Some centres also include an on-slide
positive control section. The HER2 test should be reported as
indeterminate, and repeated where possible, if technical issues
prevent one or both tests (IHC and ISH) from being reported as
positive, negative or equivocal. Examples include, inadequate
specimen handling, artefacts (eg, crush or marked edge arte-
facts) that make interpretation difﬁcult, analytical testing
failure or if controls are not as expected (ie, sample shows
strong membrane staining of normal breast tissue). In such a
case, an alternative test, or another specimen if available, should
be used to determine HER2 status. These guidelines revert to
the previously used IHC criterion of >10% cells staining for
HER214 15 instead of the >30% cut-off used in the previous
guidelines.11 16
Scoring ISH
HER2 ISH testing, which uses a dual probe method, is initially
expressed as the ratio of HER2 signal to chromosome 17
centromeric enumeration probe (CEP) signal. Subsequently the
average HER2 gene copy number reporting has been used in
some countries when using dual probe and single HER2 gene
probe methodology. The UK recommendation is to use dual
probe ISH and report the HER2/CEP17 signal ratio and HER2
copy number. Tumours showing a ratio ≥2.0 and/or a mean
HER2 gene copy number ≥6 are considered to be positive.
Assigning cases as positive based on a HER2 gene copy number
≥6 where the HER2/CEP17 ratio is <2 remains controversial
but is recommended as its inclusion aligns with national guid-
ance in other countries.21 Cases with dual-probe HER2/CEP17
ratio <2.0 with an average HER2 copy number <4.0 signals/
cells are considered as HER2 negative (ﬁgure 1). Classiﬁcation
of cases with monosomy of chromosome 17 and a HER2/
CEP17 ratio >2.0 remains controversial with uncertain anti-
HER2 treatment beneﬁt34 35 but current consensus21 is to
regard such cases as ampliﬁed.
A selection of normal cells should be assessed to conﬁrm suc-
cessful hybridisation, detection and visualisation, before assess-
ment of the invasive carcinoma. The number of chromosome
17 and HER2 signals is scored and recorded and the mean
HER2 to chromosome 17 copy ratio is calculated for 20–60
cells, where possible using at least three distinct tumour ﬁelds.
In most cases, where either clear ampliﬁcation is observed or
the ratio is below 1.5, scoring of 20 tumour cells is sufﬁcient.
Only cells in which the nuclear borders can be identiﬁed should
be counted. Overdigested, damaged and truncated nuclei should
not be scored. Only cells with minimum one copy of HER2 and
CEP17 should be scored. The location of the areas assessed
should be recorded. In cases where either tumour heterogeneity
is seen, or if the ratio is close to 2.0 or if the average copy
number is between ≥4.0 and <6.0 signals/cell, more cells
should be scored (at least 60), for details see below. Samples
with >2.0 copies of HER2 for each chromosome 17 in the
ﬁelds assessed are considered to be ampliﬁed. The HER2 ISH
test should be reported as indeterminate and a repeat/alternative
test (on the same or another specimen) is requested in the fol-
lowing situations: Controls are not as expected, nuclear reso-
lution is poor, if a signiﬁcant proportion of signals are
unscorable due to weak signals or >10% of signals occur over
cytoplasm, autoﬂuorescence is strong or the observer cannot
ﬁnd and count at least two areas of invasive tumour.
HER2 heterogeneity
Genomic heterogeneity refers to the coexistence of more than
one population of tumour cells with distinct HER2 ampliﬁca-
tion characteristics within the same tumour. Intratumoral het-
erogeneity can be seen as a clustered form where distinct
populations/clones of ampliﬁed and non-ampliﬁed tumour cells
coexist, or as a mosaic form which includes the presence of iso-
lated ampliﬁed cells in a predominantly non-ampliﬁed tumour
or a diffuse mixture of ampliﬁed and non-ampliﬁed cells across
the tumour.21 36 While such heterogeneity is generally uncom-
mon in breast cancer, the following approach has been proposed
to manage heterogeneous HER2 gene ampliﬁcation in breast
cancer and is recommended in these guidelines37:
In all cases where ISH is performed the entire slide should be
scanned before counting, areas of apparent heterogeneity should
be identiﬁed during this scan and/or by reference to an IHC
stained slide. The number of chromosome 17 (CEP17) and
HER2 signals should be counted in 20–60 non-overlapping
invasive cancer cell nuclei, using at least three distinct tumour
ﬁelds. If there is evidence of heterogeneity between ﬁelds (or
Figure 1 Recommended HER2
scoring algorithm for
immunohistochemistry (IHC) and in
situ hybridisation (ISH). *Insufﬁcient
data is available to comment on
moderate complete membrane staining
in ≤10% of tumour cells or strong
incomplete membrane staining in
>10% of tumour cells. A repeat on
another specimen/tissue block is
advisable. **Membrane staining must
be intense and uniform and resemble
chicken-wire. Ignore incomplete or
pale membrane staining in the
percentage estimation.
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less frequently within ﬁelds) additional cells (at least 20 per
ﬁeld) and/or ﬁelds (up to 6) should be counted. The HER2/
CEP17 ratio should be calculated for each ﬁeld individually.
Where the mean HER2/CEP17 ratio in any ﬁeld is 2.00 or
greater, the tumour should be regarded as ampliﬁed. For all
cases where the ratio is between 1.80 and 2.20 results should be
based on counting at least 60 tumour cells, and in cases where
heterogeneity is suspected this should be 60 cells per assessed
ﬁeld. In rare cases where ampliﬁed and non-ampliﬁed tumour
cells are intermingled in a single ﬁeld, interpretation is difﬁcult
and evidence is lacking. We suggest that for such cases only the
presence of clearly ampliﬁed cells, with multiple HER2 signals,
is considered evidence of heterogeneity, again evidence is
lacking in this area. Current evidence does not support using
the existence of small numbers of apparently ampliﬁed cells
within an individual tumour ﬁeld to identify heterogeneous
ampliﬁcation.36 38
In borderline cases, that is, those with a HER2/CEP17 ratio
of 1.80–2.20, additional cells should be counted when possible
(optimally a minimum of 60 per case), ideally this should
include a dual count (from a second observer; either internally
or in a second centre). The optimal approach to improving
accuracy in this range is to increase the number of cells counted
to 60–120, and/or repeat the test. A ratio of 1.80–1.99, after
counting further cells and/or repeating the test, should be
reported as borderline but not ampliﬁed and include a clear
statement that the carcinoma is regarded as HER2 negative
(taking the mean HER2 copy number into consideration (mean
<6 copies/cell)). A ratio of ≥2.00 should be reported as ampli-
ﬁed, and regarded as HER2 positive. Data on the response of
patients to trastuzumab whose cancers fall within the borderline
ampliﬁed category are not available; a statement to this effect
can be included in reports. While these guidelines are sufﬁcient
for the majority of cases, there are occasions when difﬁcult
cases should be referred to expert centres for guidance.
Variation increases with highly ampliﬁed samples, and is not
critical where the ratio of HER2/CEP17 exceeds 4. Where pos-
sible, count all signals, but if this is not possible, for example if
clusters are present, then try to estimate the number of signals.
Count doublets as a single signal. Where resources permit, rep-
resentative images can be captured and archived. Difﬁcult cases
should be assessed by a second observer. A minimum of 10% of
cases should be double-reported to ensure consistency between
observers.
The ISH report should include: the number of cells scored,
the average HER2 and CEP17 copy number and the HER2/
CEP17 ratio. Unusual features should be noted. For heteroge-
neous cases all these details should be reported for each sub-
clone. If there is a problem in specimen handling and/or
processing (ie, non-adherence to the guidelines), this should be
documented in the report.
Impact of heterogeneity of HER2 IHC and ISH
Although a cut-off of >10% of the invasive tumour area using
IHC is used to deﬁne positivity, cases showing complete intense
membrane staining in <10% of tumour cells are seen, albeit
rarely, and should be considered in the borderline category. In
such cases, a repeat of the HER2 IHC test on another specimen
(eg, a different tumour block) should be undertaken, to deter-
mine the percentage of positive tumour present. If this repeat
IHC assessment shows a similar pattern, ISH should be per-
formed. Variation in immunostaining between the periphery and
centre of tumours can be due to a ﬁxation gradient.
Deﬁning HER2 positivity using ISH may be complex in cases
with intratumoral heterogeneity (see above for scoring method-
ology). Such genetic heterogeneity affects a proportion of breast
cancers (11–40%36) and is more frequently seen in HER2-posi-
tive tumours. Although no clinical data is available to guide on
the likely response of genetically heterogeneous tumours har-
bouring HER2-ampliﬁed subclones to trastuzumab, it would be
valuable to standardise the deﬁnition of genetic heterogeneity to
facilitate future study of its clinical relevance.36
Evaluation
For assessment of HER2 IHC and ISH preparations, training
and experience in interpretation of histological characteristics of
breast tissue is essential. Recognition of different histological
tumour types is required. In particular, HER2 status should only
be determined on the invasive portion of the tumour, and
neither IHC nor ISH should be reported in isolation. If it is dif-
ﬁcult to differentiate invasive from in situ disease in the index
tumour block submitted for ISH, IHC markers for myoepithe-
lial cells can be used.
Image analysis systems may provide alternatives to manual
scoring for HER2 IHC and ISH. However, at present, insufﬁ-
cient evidence is available to recommend their routine use in
the diagnostic setting.
QUALITY ASSURANCE MEASURES
Controls
▸ The inclusion of controls, ideally including on-slide control
(s), and their detailed scrutiny are essential to ensure test
accuracy. Controls whose HER2 status has been validated
and producing results close to important decision-making
points are recommended. Tissue-based controls, from breast
cancers, should also be used in all assay runs, ideally showing
3+, 2+ and 1+/0 patterns. Control material should be simi-
larly ﬁxed and processed to the test tissue. Control sections
should ideally be cut at the same time as the test material.
Long-term storage of precut control sections is strongly dis-
couraged. There is no evidence that storage of blocks leads
to deterioration of signal.
▸ Cell line preparations containing multiple samples of known
HER2 status characterised by FISH and IHC and inclusion
of a tumour tissue from IHC 3+ case on each slide are
useful as additional controls.
Excessive antigen retrieval should be monitored by evaluating
normal breast epithelial cells as an internal control. Should
membrane staining be identiﬁed in the normal cell population,
excessive antigen retrieval may have occurred and retesting of
the entire run should be considered. Any such tests should cer-
tainly be interpreted with great care; it is reasonable to score a 0
or 1+ tumour as negative, but 2+ or 3+ tumours should have
staining repeated. If there is doubt between a 1+/2+ result or a
2+/3+ result, either the IHC should be repeated or ampliﬁca-
tion status should be assessed using ISH. If membrane staining
of normal epithelial cells is seen in a number of cases from the
same staining run consideration should be made to repeat stain-
ing of the whole run.
▸ Crushing and edge artefact, particularly affect core biopsies.
ISH, or repeat IHC on the surgical specimen, may be
needed. The potential gradient effects of suboptimal ﬁxation,
particularly in larger surgical specimens, must also be consid-
ered in interpretation of staining.
▸ It is essential that assay procedures be standardised so that
staining is reliable. As there can be variation between batches
of reagents, it is vital that controls are assessed critically for
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every run. New batches of antibody should also be tested
before commencing routine application. Use of standardised
operating procedures, including routine use of control mate-
rials, is recommended.
Appropriate laboratory assay methods
For IHC and ISH based HER2 testing, comprehensive standard-
isation of methodology, including monitoring of scoring proce-
dures and the inclusion of validated controls, is mandatory. In
the UK, participation and satisfactory performance in the UK
National External Quality Assessment Scheme for
Immunocytochemistry and In Situ Hybridisation (UK NEQAS
ICC & ISH) HER2 IHC and ISH modules is a requirement
(http://www.ukneqasicc.ucl.ac.uk).
Standardisation of HER2 IHC staining is best achieved by
using a commercial kit/assay. Inhouse ‘home-brew’ (laboratory
validated) methods are not recommended but, if used, strict
protocols need to be followed, including choice of antibody,
antibody dilution and retrieval method, each of which can cause
variability in staining results. If a commercial kit/assay is used, it
is recommended that laboratories adhere strictly to the kit/assay
protocol and scoring methodology. Local modiﬁcations of tech-
niques can lead to false positive and negative results. Therefore,
it is important to check and audit controls carefully in order to
ensure test accuracy. Laboratories using bright ﬁeld ISH should
perform an initial validation against FISH.
Interobserver variation in the assessment of IHC staining can
lead to misclassiﬁcation of HER2 status. Each individual asses-
sor should standardise scoring against known positive, negative
and borderline cases. It is also preferable to assess comparability
of scoring with a colleague on a regular basis. Before undertak-
ing evaluation of HER2, assessors should receive relevant
training.
Published data suggest that interobserver variation is signiﬁ-
cantly lower for FISH than for IHC. However, especially when
developing a new service, care needs to be taken. The recom-
mendation is that laboratories should perform validation studies
by dual observer scoring when training new staff until there is
concordance of 95%. For ISH validation purposes, each staff
member should perform a minimum of 100 ISH tests in parallel
with an experienced ISH scorer to attain a minimum concord-
ance of 95% on diagnostic results (ampliﬁed and non-ampliﬁed
status) and numerical results (for HER2 and CEP17). Continued
monitoring of scoring offers advantages in quality control and
training, but is not a requirement.
Validation of standardised assay methodology
Test conditions should be optimised so that distinct moderate or
strong membrane staining shows >90% concordance with
HER2 ISH positive samples. This can be achieved by:
1. Dual HER2 IHC and ISH assay of a contemporary series of
breast carcinomas (minimum 100 cases). Use of tumour
tissue array blocks for this purpose may reduce costs. HER2
ISH assay can be conﬁned to those cases demonstrating 3+,
2+ and 1+ membrane reactivity.
2. Alternatively, a series of carcinomas that have already been
scored for HER2 IHC and ISH, from a reference laboratory,
can be used.
Laboratories not able to standardise inhouse methodology
should also consider using a commercial validated kit assay
system.
ISH for HER2 gene evaluation
ISH testing for HER2 should meet the following criteria:
1. Comprehensive standardisation of methodology
2. Validated controls: the inclusion of a chromosome 17 probe
to allow for correction of the HER2 signal number for
chromosome 17 aneusomy (seen in ∼30% of cases and report-
edly more common in tumours that show discrepant HER2
expression and in tumours with discordant HER2-protein and
gene copy number measurements) is recommended.
Case load
▸ Laboratories providing a testing service should be carrying
out a minimum of 250 assays per year for immunohisto-
chemical detection of HER2. This target level has been set to
ensure higher consistency of assay quality and continuing
expertise of assay providers.
▸ Centres with low numbers of cases (<250 per year) should
consider using a reference laboratory service.
▸ Similar principles apply to ISH testing; it is recommended
that laboratories testing < 100 cases per year (<150 includ-
ing gastric carcinomas) consider referral of their workload to
a reference laboratory. A smaller case load has been set for
ISH assay, as it is generally accepted to be a more discrimin-
ant test at the positive–negative borderline, has greater ease
of methodological standardisation, and has less observer
variation.
General principles
ISH should be performed on the same block as used for IHC. It
is advisable that areas of the invasive carcinoma to be scored
with ISH are located using a serial section stained with H&E
and HER2 IHC where available. Care should be taken to avoid
areas of ductal carcinoma in situ, which can show ampliﬁcation
even when adjacent invasive tumour cells are negative.
Tissue digestion should be standardised to maintain nuclear
morphology and should follow strict protocols. Some laborator-
ies ﬁnd it helpful to evaluate nuclear structure before hybridisa-
tion and to adjust digestion, where appropriate, to preserve
nuclear integrity. This may be particularly valuable with difﬁcult
sections, bone biopsies, etc. Evaluation of sections before
hybridisation can also improve efﬁciency and is recommended.
Hybridisation and washing steps should be standardised.
Guidance can be provided by the reference laboratories. Use of
automated tissue processors and standardised commercial tissue
digestion kits can improve consistency and should be
considered.
It is recommended that commercially available validated
probes are used. There are a number of commercial kits for
HER2 ISH using ﬂuorescence and chromogen based detection
systems and which are all acceptable, once properly validated.
Short turnaround times for HER2 testing that do not delay the
management of patients are recommended. Turnaround time is
recognised to be variable between different centres, and can be
addressed at the level of cancer networks and local services
(ﬁgure 2). The National Institute for Care Excellence recommends
that HER2 status of the tumour be assessed and the results made
available within 2 weeks to allow planning of systemic treatment
by the MDTand that local arrangements and written clinical pro-
tocols are in place to ensure HER2 status results are available
within this time (http://publications.nice.org.uk/breast-cancer-
quality-standard-qs12/quality-statement-5-pathology-er-and-her2-
status#quality-measure-5). It is also important to emphasise the
role of improved communication between pathologists/laborator-
ies performing the test and clinicians to ensure proper handling of
specimens (ie, preﬁxation time and ﬁxation type), short turn-
around time and proper interpretation of the test results.
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Audit
Regular and ongoing audit should be undertaken. Laboratories
should audit their overall positive rate for HER2 using a com-
bination of IHC and ISH. It is important to ensure that the
sample size is adequate. Of note, the average proportion of
invasive breast cancer cases recorded as HER2-positive is 14.5%
(UK NEQAS ICC & ISH combined 5 year national audit data),
with 14.3% of primary carcinomas and 18% of metastatic cases
being HER2-positive (table 1). Of these cases approximately
22% cases are reported as borderline (2+) on IHC; of which
15–16% are reported as HER2 ISH ampliﬁed.16 The proportion
of HER2-positive breast cancers found in screen detected breast
cancer cases is recognised to be lower than in symptomatic prac-
tice. Audit of HER2 assay turnaround time is also important as
it is critical to patient pathway.
Quality assurance for HER2 receptor evaluation in the UK
All UK clinical laboratories using IHC or ISH to assess HER2
status as a predictive marker must participate in an appropriate
external quality assurance programme, such as that run by the
UK NEQAS ICC & ISH.
Communication
In the era of personalised medicine and the commonplace
routine practice of MDT meeting for discussion of diagnosis
and management of all patients with cancer in the UK,
improved communication within the team is considered of para-
mount importance. Although for many years there has been
collaboration between pathologists and patient-facing clinicians in
the UK, this guideline further emphasises the importance of this
collaboration. Close communication with surgeons and radiolo-
gists is therefore advised in order to improve control over samples
preﬁxation time and ﬁxation type, and with oncologists to
improve understanding of interpretation of the results. This is also
expected to facilitate control over HER2 test turnaround time.
In conclusion, this update contains recommendations sup-
ported by a sufﬁcient level of evidence on key points related to
HER2 testing methodology, testing algorithm, interpretation of
the results and the potential need for retesting. Laboratories
offering a HER2 testing service and pathologists, oncologists
and surgeons involved in test interpretation and clinical use
should do their best to adhere to published guidelines and
ensure accurate performance and interpretation of such tests.
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Table 1 Proportion of HER2-positive primary and metastatic
breast cancers*
0 1+ 2+ 3+ ISH +
Overall HER2-
positive
Overall (%) 32.8 33.1 21.8 11.6 14.7 14.5
Primary carcinoma (%) 32.6 33.7 21.8 11.5 14.6 14.3
Metastatic lesion (%) 36.7 27.2 21.1 14.9 15.8 18.0*
*UK NEQAS ICC & ISH combined 5 year national audit data (unpublished data).
ISH, in situ hybridisation; ISH+, proportion of 2+ carcinomas that are amplified; UK
NEQAS ICC & ISH, UK National External Quality Assessment Scheme for
Immunocytochemistry and In Situ Hybridisation.
Figure 2 Pathway for HER2 testing.
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